Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
11:43am, Tuesday, 02'nd Dec 2025
Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Capital Fund Management S.A. Grows Holdings in Neurocrine Biosciences, Inc. $NBIX
04:18am, Friday, 28'th Nov 2025
Capital Fund Management S.A. lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 15.9% during the undefined quarter, according to the company in its most recent 13F filing
Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now
01:46pm, Thursday, 27'th Nov 2025
Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Creative Planning Raises Position in Neurocrine Biosciences, Inc. $NBIX
04:03am, Thursday, 27'th Nov 2025
Creative Planning lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 31.6% during the undefined quarter, according to the company in its most recent 13F filing with the SEC.
Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight important differences between treatments Review pr
17 Capital Partners LLC Buys 650 Shares of Neurocrine Biosciences, Inc. $NBIX
04:04am, Thursday, 20'th Nov 2025
17 Capital Partners LLC lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 22.3% during the undefined quarter, according to its most recent 13F filing with the Securities and
A Strong Crenessity Launch And Muscarinic Pipeline Can Propel Neurocrine Biosciences Further
11:56pm, Tuesday, 18'th Nov 2025
Neurocrine Biosciences looks meaningfully undervalued, with ongoing growth from Ingrezza, a strong launch for Crenessity, and a promising pipeline. NBIX is looking to grow Ingrezza's market share with
Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies London Healthcare Conference 2025 Transcript
09:18am, Tuesday, 18'th Nov 2025
Neurocrine Biosciences, Inc. ( NBIX ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:00 AM EST Company Participants Kyle Gano - CEO & Director Eric Benevich - Chief Commercial Officer
Allworth Financial LP Purchases 2,845 Shares of Neurocrine Biosciences, Inc. $NBIX
03:43am, Monday, 17'th Nov 2025
Allworth Financial LP increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 2,107.4% in the second quarter, according to its most recent disclosure with the Securities and
Banco Bilbao Vizcaya Argentaria S.A. Raises Stock Holdings in Neurocrine Biosciences, Inc. $NBIX
03:58am, Saturday, 15'th Nov 2025
Banco Bilbao Vizcaya Argentaria S.A. lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 3.1% during the second quarter, according to the company in its most recent disclosure
Neurocrine Biosciences to Present at Upcoming Investor Conferences
04:01pm, Tuesday, 11'th Nov 2025
SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences: Jeffer
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice
01:45pm, Tuesday, 11'th Nov 2025
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile
12:51pm, Tuesday, 11'th Nov 2025
On Monday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) said its Phase 2 study of NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo, though it wa
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
04:05pm, Monday, 10'th Nov 2025
SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compoun
Earnings Estimates Rising for Neurocrine (NBIX): Will It Gain?
01:21pm, Thursday, 06'th Nov 2025
Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
